DB:0QF

Stock Analysis Report

Executive Summary

Moderna, Inc., a clinical stage biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, and cardiovascular diseases.


Snowflake Analysis

Flawless balance sheet with limited growth.


Similar Companies

Share Price & News

How has Moderna's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 0QF's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-5.1%

0QF

0.4%

DE Biotechs

-0.9%

DE Market


1 Year Return

-6.6%

0QF

10.0%

DE Biotechs

12.8%

DE Market

Return vs Industry: 0QF underperformed the German Biotechs industry which returned 10% over the past year.

Return vs Market: 0QF underperformed the German Market which returned 12.8% over the past year.


Shareholder returns

0QFIndustryMarket
7 Day-5.1%0.4%-0.9%
30 Day-13.1%-3.2%-0.4%
90 Day-9.8%4.6%2.3%
1 Year-6.6%-6.6%10.3%10.0%16.3%12.8%
3 Yearn/a49.4%47.8%15.8%5.7%
5 Yearn/a13.9%11.5%19.7%3.3%

Price Volatility Vs. Market

How volatile is Moderna's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Moderna undervalued compared to its fair value and its price relative to the market?

4.84x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate 0QF's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate 0QF's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: 0QF is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: 0QF is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 0QF's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 0QF is overvalued based on its PB Ratio (4.8x) compared to the DE Biotechs industry average (3.5x).


Next Steps

Future Growth

How is Moderna forecast to perform in the next 1 to 3 years based on estimates from 9 analysts?

0.5%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 0QF is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 0QF is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 0QF is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: 0QF's revenue (21.2% per year) is forecast to grow faster than the German market (5.2% per year).

High Growth Revenue: 0QF's revenue (21.2% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: 0QF is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has Moderna performed over the past 5 years?

-78.8%

Last years earnings growth


Earnings and Revenue History

Quality Earnings: 0QF is currently unprofitable.

Growing Profit Margin: 0QF is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if 0QF's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare 0QF's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 0QF is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.7%).


Return on Equity

High ROE: 0QF has a negative Return on Equity (-42.53%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Moderna's financial position?


Financial Position Analysis

Short Term Liabilities: 0QF's short term assets ($1.1B) exceed its short term liabilities ($147.8M).

Long Term Liabilities: 0QF's short term assets ($1.1B) exceed its long term liabilities ($191.3M).


Debt to Equity History and Analysis

Debt Level: 0QF is debt free.

Reducing Debt: 0QF had no debt 5 years ago.


Balance Sheet

Inventory Level: 0QF has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if 0QF's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 0QF has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: 0QF has sufficient cash runway for 2.2 years if free cash flow continues to reduce at historical rates of -40.7% each year.


Next Steps

Dividend

What is Moderna's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.3%markettop25%3.6%industryaverage1.0%forecastin3Years0%

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate 0QF's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate 0QF's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 0QF's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 0QF's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 0QF's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.3yrs

Average management tenure


CEO

Stéphane Bancel (46yo)

8.3yrs

Tenure

US$58,608,484

Compensation

Mr. Stéphane Bancel serves as Interim President of Valera LLC. Mr. Bancel is Venture Partner of Flagship Pioneering and a Trustee of the Museum of Science in Boston. Mr. Bancel provides strategic counsel a ...


CEO Compensation Analysis

Compensation vs Market: Stéphane's total compensation ($USD58.61M) is above average for companies of similar size in the German market ($USD3.37M).

Compensation vs Earnings: Stéphane's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Noubar Afeyan
Co-Founder8yrsUS$429.75k0.17% $10.1m
Stéphane Bancel
CEO & Director8.3yrsUS$58.61m2.06% $125.3m
Lorence Kim
CFO & Treasurer5.8yrsUS$9.04m0.36% $21.9m
Stephen Hoge
President0yrsUS$23.95m0.57% $34.7m
Jennifer Lee
Chief Accounting Officer0yrsno datano data
Juan Andres
Chief Technical Operations & Quality Officer2.5yrsno datano data
John Reynders
Chief Information Officer6.6yrsno datano data
Melissa Moore
Chief Scientific Officer & Member of Scientific Advisory Board0yrsno datano data
Lavina Talukdar
Head of Investor Relations0.8yrsno datano data
Lori Henderson
General Counsel & Corporate Secretary1.8yrsno datano data

3.3yrs

Average Tenure

50.5yo

Average Age

Experienced Management: 0QF's management team is considered experienced (3.3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Noubar Afeyan
Co-Founder8yrsUS$429.75k0.17% $10.1m
Stéphane Bancel
CEO & Director8.3yrsUS$58.61m2.06% $125.3m
Melissa Moore
Chief Scientific Officer & Member of Scientific Advisory Board0yrsno datano data
Robert Langer
Director & Member of Scientific Advisory Board9.2yrsUS$408.03k3.17% $193.2m
Elizabeth Nabel
Independent Director4.2yrsUS$388.75k0.012% $744.1k
Ulrich von Andrian-Werburg
Member of Scientific Advisory Board0yrsno datano data
Jack Szostak
Chairman of Scientific Advisory Board0yrsno datano data
John Aunins
Member of Technology Advisory Board5.8yrsno datano data
Israel Ruiz
Independent Director3yrsUS$405.98k0.0013% $76.7k
Stephen Berenson
Independent Director2.3yrsUS$403.48k0.0063% $382.4k

5.8yrs

Average Tenure

58yo

Average Age

Experienced Board: 0QF's board of directors are considered experienced (5 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: 0QF insiders have sold more shares than they have bought in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 324.6%.


Top Shareholders

Company Information

Moderna, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Moderna, Inc.
  • Ticker: 0QF
  • Exchange: DB
  • Founded: 2010
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$6.615b
  • Listing Market Cap: US$6.090b
  • Shares outstanding: 362.85m
  • Website: https://www.modernatx.com

Number of Employees


Location

  • Moderna, Inc.
  • 200 Technology Square
  • Cambridge
  • Massachusetts
  • 2139
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
MRNANasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDDec 2018
0QFMUN (Boerse Muenchen)YesCommon StockDEEURDec 2018
0QFDB (Deutsche Boerse AG)YesCommon StockDEEURDec 2018
MRNA *BMV (Bolsa Mexicana de Valores)YesCommon StockMXMXNDec 2018

Biography

Moderna, Inc., a clinical stage biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, and cardiovascular diseases. As of February 15, 2019 the company had 11 programs in clinical trials and a total of 20 development candidates in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. It has strategic alliances with AstraZeneca, Merck & Co., Vertex Pharmaceuticals, Biomedical Advanced Research and Development Authority, Defense Advanced Research Projects Agency, and Bill & Melinda Gates Foundation; and a research collaboration with Harvard University. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/24 01:01
End of Day Share Price2020/02/21 00:00
Earnings2019/09/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.